Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment

J Thorac Oncol. 2013 Feb;8(2):e19-20. doi: 10.1097/JTO.0b013e31827ce38e.
No abstract available

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / genetics
  • Adenocarcinoma / pathology
  • Adenocarcinoma / prevention & control*
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bevacizumab
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Carcinoma, Non-Small-Cell Lung / prevention & control*
  • Exons / genetics*
  • Female
  • Humans
  • Lapatinib
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Lung Neoplasms / prevention & control*
  • Middle Aged
  • Mutation / genetics*
  • Prognosis
  • Quinazolines / administration & dosage
  • Receptor, ErbB-2 / antagonists & inhibitors
  • Receptor, ErbB-2 / genetics*
  • Trastuzumab
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Antibodies, Monoclonal, Humanized
  • Quinazolines
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Lapatinib
  • Bevacizumab
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Trastuzumab